Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The N-methyl-D-aspartate receptor (NMDAR) glycine co-agonist site is a critical regulatory locus located on the GluN1 and GluN3 subunits of the NMDAR complex (UniProt: P05231). Unlike most ligand-gated ion channels, the NMDAR requires the simultaneous binding of two different agonists—glutamate and a co-agonist like glycine or D-serine—to open its central pore and allow cation influx (StatPearls: NMDA Receptor). This site is distinct from the inhibitory glycine receptor and is often termed the strychnine-insensitive site. Biologically, it is essential for mediating synaptic plasticity and long-term potentiation, which are the cellular foundations of learning and memory. In disease states, NMDAR hypofunction at this site is a core component of the glutamate hypothesis of schizophrenia, contributing to cognitive and negative symptoms (PubMed: 18408235). Conversely, excessive activation of the receptor can lead to calcium-induced excitotoxicity, which is implicated in stroke and neurodegenerative conditions. Pharmacological agents targeting this site include agonists and partial agonists like D-cycloserine, which are used to enhance NMDAR signaling, and antagonists like gavestinel, which have been explored for neuroprotection (PubChem: CID 784).
Drugs targeting this site act as co-agonists, partial agonists, or competitive antagonists to modulate the opening of the NMDA receptor ion channel, thereby regulating calcium and sodium influx into the neuron (StatPearls: NMDA Receptor).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-methyl-D-aspartate receptor (NMDAR) glycine co-agonist site (NMDAR glycine site).